TP53 and renal cell carcinoma: These authors proposed that (1) positive p53 immunostaining in RCC is associated with metastatic disease and poor survival in patients with early-stage disease, and (2) TP53/p53 mutations in RCC may contribute to the acquisition of metastatic potential [131].